Health Professional Radio - Podcast

Dr. Gail McIntyre, CEO of Aravive, Inc., discusses the urgent need for improved therapeutic approaches to treat patients with ovarian cancer who are resistant to standard of care therapy and have limited treatment options. She explains the challenges with current treatment therapies and talks about Aravive's lead product candidate, AVB-500, a unique and promising treatment approach for platinum resistant ovarian cancer.The company expects to initiate a pivotal trial during the first quarter of 2021.